Press release
Eczema Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2025
Discover the latest drugs and treatment options in the Eczema Pipeline. Dive into DelveInsight's comprehensive report today! @ Eczema Pipeline Outlook [https://www.delveinsight.com/sample-request/eczema-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Eczema Pipeline Report
* In July 2025, Pfizer announced a study is being conducted to find out if the test medicine, abrocitinib, improves eczema and is safe for children 6 to
* In July 2025, Inmagene LLC announced a study is to evaluate the efficacy and safety of different dose regimens of IMG-007, compared to placebo. A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety profile of various dose regimens of IMG-007 in adult participants with moderate-to-severe active atopic dermatitis (AD) up to 52 weeks.
* In July 2025, Kymab Limited conducted a Phase IIb 5-arm study to assess the effect of Anti-OX40L Monoclonal Antibody (KY1005) in adult participants with moderate to severe atopic dermatitis.
* DelveInsight's Eczema pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Eczema treatment.
* The leading Eczema Companies such as Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries, Brickell Biotech Inc., Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics , and others.
* Promising Eczema Pipeline Therapies such as alitretinoin, Arctiva, KY1005, Dupilumab, Lebrikizumab, Baricitinib, MEDI9929, Midazolam, Omeprazole , and others.
Stay ahead with the most recent pipeline outlook for Eczema. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Eczema Treatment Drugs [https://www.delveinsight.com/sample-request/eczema-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Eczema Emerging Drugs Profile
* Amlitelimab: Kymab
Amlitelimab SAR445229 (formerly KY1005) is a human monoclonal antibody that targets OX40L, a key regulator of the immune system. Amlitelimab is designed to rebalance the immune system by blocking inappropriate activation and proliferation of 'pro-inflammatory' effector T cells and promoting expansion of 'anti-inflammatory' regulatory T cells, without broad suppression of the immune system. It is believed this mechanism-of-action means Amlitelimab could be applicable to a range of autoimmune and inflammatory diseases. In Phase I clinical trial in healthy volunteers, Amlitelimab was able to block T cell-driven skin inflammation while being well tolerated. It is believed the immune-modulating mechanism of Amlitelimab has broad potential therapeutic application in multiple diseases caused by immune dysregulation. Currently, the drug is being developed in the Phase II stage of clinical trial evaluation for the treatment of Eczema.
* BX 005: BiomX
BX005, a topical phage cocktail that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease. In preclinical in vitro studies, BX005 was shown to be active against over 90% of strains of S. aureus isolated from the skin of subjects from U.S. and Europe, including antibiotic resistant strains. Currently, the drug is being developed in the Phase I/II stage of clinical trial evaluation for the treatment of Atopic Dermatitis.
* LP 0145: LEO Pharma
LP 0145, is an anti-inflammatory monoclonal antibody under development for atopic dermatitis. Currently, the drug is being developed in the Phase II stage of clinical trial evaluation for the treatment of Eczemas.
The Eczema Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Eczema with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Eczema Treatment.
* Eczema Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Eczema Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Eczema market
Explore groundbreaking therapies and clinical trials in the Eczema Pipeline. Access DelveInsight's detailed report now! @ New Eczema Drugs [https://www.delveinsight.com/sample-request/eczema-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Eczema Companies
Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries, Brickell Biotech Inc., Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics , and others.
Eczema Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal
Eczema Products have been categorized under various Molecule types such as
* Oligonucleotide
* Peptide
* Small molecule
Unveil the future of Eczema Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Eczema Market Drivers and Barriers [https://www.delveinsight.com/sample-request/eczema-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Eczema Pipeline Report
* Coverage- Global
* Eczema Companies- Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries, Brickell Biotech Inc., Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics , and others.
* Eczema Pipeline Therapies- alitretinoin, Arctiva, KY1005, Dupilumab, Lebrikizumab, Baricitinib, MEDI9929, Midazolam, Omeprazole , and others.
* Eczema Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Eczema Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Eczema Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Eczema Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/eczema-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Eczema: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Eczema- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Drug name : Company name
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Amlitelimab: Kymab
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug name : Company name
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name : Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Eczema Key Companies
* Eczema Key Products
* Eczema- Unmet Needs
* Eczema- Market Drivers and Barriers
* Eczema- Future Perspectives and Conclusion
* Eczema Analyst Views
* Eczema Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=eczema-pipeline-fda-approvals-clinical-trials-developments-and-companies-2025]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/eczema-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Eczema Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2025 here
News-ID: 4123585 • Views: …
More Releases from ABNewswire
Adapts.ai Redefines Software Maintenance and Modernization with GenAI-Powered Pl …
October 10, 2025 - In an era where digital transformation defines competitive advantage, Adapts.ai is emerging as a game-changer in enterprise application modernization and AI-driven digital transformation services. The platform leverages next-generation GenAI technology to simplify software maintenance, accelerate legacy code modernization, and empower engineering teams with intelligent automation.
Adapts addresses one of the most pressing challenges in modern software engineering - navigating outdated, poorly documented, and complex legacy codebases. Traditional…
A Journey Across Oceans and Generations: "From Germany With Love" Uncovers One F …
Julie Anne Brion never set out to write a history book. What she did want was to understand where she came from, and maybe, just maybe, help others feel a little less lost in their own search for belonging. The result is her newest book, From Germany With Love: Mit Liebe aus Deutschland , a deeply personal look at one family's journey from the heart of Europe to the promise…
New Book from Immigration Attorney Shares Practical Guidance for Securing a U.S. …
New York, NY - Immigrants working toward permanent residency in the United States now have a new guide to help them through the process. Anne Zeitoun-Sedki, an immigration attorney with more than 15 years of hands-on experience, whose YouTube channel has attracted millions of views worldwide, has published a book that simplifies the path to a U.S. green card.
The book draws on Zeitoun-Sedki's years of representing individuals and families from…
Kinghelm Antennas Power OBD Applications in Smart and New Energy Vehicles
Kinghelm, a leading RF and microwave technology company, provides high-performance antennas and connectors for OBD systems in smart and new energy vehicles. Together with partners Slkor Semiconductor and Avant Electronics, Kinghelm delivers integrated solutions for GPS/BDS positioning, Bluetooth/Wi-Fi transmission, and intelligent vehicle connectivity.
Image: https://www.abnewswire.com/upload/2025/10/0790f023c90e731790a4ec80533af9ea.jpg
Automotive OBD Products and Application Scenarios
As intelligent connected vehicles become increasingly mainstream, On-Board Diagnostics (OBD) systems have emerged as a vital component for ensuring driving safety, emissions…
More Releases for Eczema
Global Parents for Eczema Research (GPER) Announces 2025 Childhood Eczema Preven …
Santa Barbara, CA, September 9, 2025 - A decade ago, Global Parents for Eczema Research (GPER) was founded with a simple but powerful mission: to reduce the suffering of children with eczema and to give parents a voice in shaping research priorities. Today, GPER is carrying that mission forward by directly funding innovative science to make rapid progress towards a cure and prevention.
GPER is excited to announce the recipients of…
Hand Eczema Market Massive Growth opportunity Ahead
Introduction
Hand eczema, a chronic inflammatory skin condition affecting the hands, is one of the most common occupational skin disorders worldwide. Characterized by itching, redness, scaling, and painful cracks, it can severely impair daily activities and quality of life. The condition is prevalent among healthcare workers, hairdressers, construction workers, and others exposed to irritants and allergens.
With increasing awareness of skin health, growth in dermatological research, and the introduction of novel therapies…
Codex Labs to Exhibit at the National Eczema Association's Eczema Expo 2025
Scottsdale, Ariz. - July 17th, 2025 - Codex Labs [https://www.codexlabscorp.com/], a biotech skincare company focused on microbiome-friendly solutions, is honored to participate in the National Eczema Association's Eczema Expo 2025 [https://nationaleczema.org/eczema-expo/?gad_source=1&gad_campaignid=22351487646&gbraid=0AAAAAB0npNbWbfjE80zPi-DhIw2YfY2qF&gclid=CjwKCAjw3f_BBhAPEiwAaA3K5GPLZHZHEl6Qy8xrAj3hEWhfW7WDsCE-7pymOFKmLfLmr43e1AAXYhoC90YQAvD_BwE]. Taking place from July 24th to 27th at the Grand Hyatt Scottsdale Resort, individuals impacted by eczema will gather to learn from world-class medical experts and community leaders. The goal of the event is to provide you with support,…
Global Parents for Eczema Research (GPER) Awards Two Grants to Advance Childhood …
Santa Barbara, CA, October 15, 2024 - Global Parents for Eczema Research (GPER), a nonprofit organization dedicated to improving the lives of children suffering from eczema (atopic dermatitis, AD), announced the funding of two groundbreaking research projects as part of its 2024 Childhood Eczema Prevention Grant program. These grants will each provide up to $25,000 to support clinical research focused on preventing eczema in children.
Eczema affects up to 20% of…
Global Parents for Eczema Research (GPER) Announces Childhood Eczema Prevention …
Santa Barbara, CA, March 11, 2024 - Global Parents for Eczema Research (GPER) today announced the release of its Childhood Eczema Prevention Grant aimed at supporting innovative research studies focused on preventing pediatric atopic dermatitis (AD or "eczema"). This funding announcement is aimed at addressing the increasing prevalence of AD among children and at fostering research initiatives with the potential to mitigate the burden on children and families.
"We are dedicated…
Eczema Treatment Market During 2017 to 2025
Eczema, also referred as dermatitis or atopic dermatitis, is a disease which results in inflammation of the skin. Eczema is characterized by rash, red skin, and itchiness. The area of the skin involved may vary from small to the entire body. Few combination of factors such as genetical factor, abnormal function of immune system, environmental factor, defects in skin barrier, and activities may cause the skin to be extremely sensitive.…
